Free Trial

Quadrature Capital Ltd Has $7.70 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories logo with Medical background

Quadrature Capital Ltd lifted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 87.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,820 shares of the medical research company's stock after acquiring an additional 11,135 shares during the period. Quadrature Capital Ltd owned approximately 0.08% of Bio-Rad Laboratories worth $7,699,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in BIO. Victory Capital Management Inc. grew its holdings in Bio-Rad Laboratories by 48.7% during the 4th quarter. Victory Capital Management Inc. now owns 17,671 shares of the medical research company's stock valued at $5,706,000 after purchasing an additional 5,790 shares in the last quarter. Artisan Partners Limited Partnership boosted its stake in Bio-Rad Laboratories by 38.2% during the 4th quarter. Artisan Partners Limited Partnership now owns 151,691 shares of the medical research company's stock valued at $48,980,000 after acquiring an additional 41,937 shares during the last quarter. Lecap Asset Management Ltd. bought a new position in Bio-Rad Laboratories during the 4th quarter valued at $1,590,000. Comerica Bank bought a new position in Bio-Rad Laboratories during the 3rd quarter valued at $11,054,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in Bio-Rad Laboratories during the 4th quarter valued at $2,609,000. Institutional investors and hedge funds own 65.24% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on BIO. Citigroup downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $400.00 to $365.00 in a research note on Wednesday, April 3rd. Jefferies Financial Group restated a "hold" rating and issued a $315.00 price target (down from $440.00) on shares of Bio-Rad Laboratories in a research report on Monday, June 3rd. UBS Group reduced their price target on shares of Bio-Rad Laboratories from $420.00 to $385.00 and set a "buy" rating on the stock in a research report on Wednesday, May 8th. Finally, upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Tuesday, May 28th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $436.67.

Read Our Latest Stock Analysis on Bio-Rad Laboratories

Bio-Rad Laboratories Stock Performance

NYSE:BIO traded down $6.89 during mid-day trading on Tuesday, hitting $288.88. The stock had a trading volume of 398,628 shares, compared to its average volume of 211,116. The stock has a market capitalization of $8.24 billion, a price-to-earnings ratio of -27.89 and a beta of 0.95. The company has a 50 day simple moving average of $287.82 and a 200-day simple moving average of $312.05. Bio-Rad Laboratories, Inc. has a 52 week low of $261.59 and a 52 week high of $431.79. The company has a current ratio of 6.57, a quick ratio of 4.89 and a debt-to-equity ratio of 0.13.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its earnings results on Tuesday, May 7th. The medical research company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.04 by $0.25. The firm had revenue of $610.82 million for the quarter, compared to analysts' expectations of $619.09 million. Bio-Rad Laboratories had a negative net margin of 12.37% and a positive return on equity of 3.59%. Bio-Rad Laboratories's quarterly revenue was down 9.8% on a year-over-year basis. During the same quarter last year, the company earned $3.34 EPS. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.8 earnings per share for the current fiscal year.

Insider Buying and Selling at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 369 shares of the firm's stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $281.91, for a total transaction of $104,024.79. Following the transaction, the executive vice president now owns 6,573 shares of the company's stock, valued at approximately $1,852,994.43. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 17.50% of the stock is owned by corporate insiders.

Bio-Rad Laboratories Profile

(Free Report)

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Featured Stories

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Should you invest $1,000 in Bio-Rad Laboratories right now?

Before you consider Bio-Rad Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.

While Bio-Rad Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines